Meeting
2016 ASCO Annual Meeting
Phase 2 study of anastrozole in recurrent estrogen (ER) / progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903.
Authors
Linda R. Mileshkin
Peter MacCallum Cancer Centre, Melbourne, Australia
Linda R. Mileshkin , Richard J Edmondson , Rachel O'Connell , Katrin Marie Sjoquist , David Cannan , Rema Jyothirmayi , Philip James Beale , Tony Bonaventura , Jeffrey C. Goh , Marcia Hall , Andrew R. Clamp , John A. Green , Rosemary Lord , James Scurry , Michael Friedlander
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
ACTRN12610000796088
Citation
J Clin Oncol 34, 2016 (suppl; abstr 5520)
DOI
10.1200/JCO.2016.34.15_suppl.5520
Abstract #
5520
Poster Bd #
343
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
CCTG EN10: A phase II study of tailored adjuvant therapy in POLE-mutated and p53-wildtype/NSMP early-stage endometrial cancer (EC)—RAINBO BLUE and TAPER.
First Author: Jessica N. McAlpine
Poster
2012 Breast Cancer Symposium
Estrogen receptor-positive, progesterone receptor-negative tumors: Pathology and outcome correlations from a single-center cohort.
First Author: Oana Danciu
Poster
2023 ASCO Annual Meeting
A phase II, randomized, double-blind study of the use of rucaparib vs placebo maintenance therapy in metastatic and recurrent endometrial cancer.
First Author: Bradley Corr
Poster
2023 ASCO Annual Meeting
OATH trial: A phase II clinical trial evaluating the combination of onapristone with anastrozole for women with hormone receptor positive endometrial cancer—Preliminary results.
First Author: Russell J. Schilder